Dibb M, Ang YS. Targeting the cell cycle in esophageal adenocarcinoma: An adjunct to anticancer treatment. World J Gastroenterol 2011; 17(16): 2063-2069 [PMID: 21547123 DOI: 10.3748/wjg.v17.i16.2063]
Corresponding Author of This Article
Yeng S Ang, MD, FRCP, FRCPI, FEBG, Consultant Gastroenterologist/Honorary Senior Lecturer, Royal Albert Edward Infirmary, Wigan Lane, Wigan WN1 2NN, United Kingdom. yeng.ang@wwl.nhs.uk
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 28, 2011; 17(16): 2063-2069 Published online Apr 28, 2011. doi: 10.3748/wjg.v17.i16.2063
Targeting the cell cycle in esophageal adenocarcinoma: An adjunct to anticancer treatment
Martyn Dibb, Yeng S Ang
Martyn Dibb, Department of Gastroenterology, Royal Albert Edward Infirmary, Wigan Lane, Wigan WN1 2NN, United Kingdom
Yeng S Ang, School of Translational Medicine, Faculty of Medical and Human Sciences, The University of Manchester, Manchester M13 9PL, United Kingdom
Author contributions: Literature review and manuscript by Dibb M, concepts and corrections by Ang YS.
Supported by UK National Institute of Health Research/Cancer Research Network and Research and Development Department of Wrightington Wigan and Leigh NHS Foundation Trust (to Ang YS); Wrightington Wigan and Leigh NHS Foundation Trust Cancer Therapy Fund (to Dibb M)
Correspondence to: Yeng S Ang, MD, FRCP, FRCPI, FEBG, Consultant Gastroenterologist/Honorary Senior Lecturer, Royal Albert Edward Infirmary, Wigan Lane, Wigan WN1 2NN, United Kingdom. yeng.ang@wwl.nhs.uk
Telephone: +44-1942-773119 Fax: +44-1942-822340
Received: December 2, 2010 Revised: January 11, 2011 Accepted: January 18, 2011 Published online: April 28, 2011
Abstract
Esophageal adenocarcinoma is a major cause of cancer death in men in the developed world. Continuing poor outcomes with conventional therapies that predominantly target apoptosis pathways have lead to increasing interest in treatments that target the cell cycle. A large international effort has led to the development of a large number of inhibitors, which target cell cycle kinases, including cyclin-dependent kinases, Aurora kinases and polo-like kinase. Initial phase I/II trials in solid tumors have often demonstrated only modest clinical benefits of monotherapy. This may relate in part to a failure to identify the patient populations that will gain the most clinical benefit. Newer compounds lacking the side effect profile of first-generation compounds may show utility as adjunctive treatments targeted to an individual’s predicted response to treatment.
